CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 130 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 2.94 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,438 | -18.0% | 96,481 | -39.7% | 0.08% | -11.4% |
| Q2 2023 | $1,753 | +53.2% | 160,081 | +22.1% | 0.09% | +72.5% |
| Q1 2023 | $1,144 | +38.8% | 131,141 | -0.1% | 0.05% | +27.5% |
| Q4 2022 | $824 | -99.8% | 131,300 | -1.3% | 0.04% | +81.8% |
| Q3 2022 | $465,000 | +18.6% | 133,000 | 0.0% | 0.02% | +29.4% |
| Q2 2022 | $392,000 | -5.1% | 133,000 | 0.0% | 0.02% | +6.2% |
| Q1 2022 | $413,000 | -19.8% | 133,000 | -12.8% | 0.02% | 0.0% |
| Q4 2021 | $515,000 | +24.1% | 152,500 | +34.4% | 0.02% | +23.1% |
| Q3 2021 | $415,000 | -16.7% | 113,500 | -0.6% | 0.01% | -23.5% |
| Q2 2021 | $498,000 | -3.9% | 114,200 | 0.0% | 0.02% | -5.6% |
| Q1 2021 | $518,000 | +0.8% | 114,200 | +27.6% | 0.02% | 0.0% |
| Q4 2020 | $514,000 | -32.9% | 89,500 | -15.4% | 0.02% | -28.0% |
| Q3 2020 | $766,000 | +95.4% | 105,800 | -5.9% | 0.02% | +127.3% |
| Q2 2020 | $392,000 | +273.3% | 112,400 | +361.8% | 0.01% | +266.7% |
| Q1 2017 | $105,000 | – | 24,341 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 1,641,804 | $7,454,000 | 6.54% |
| COMMODORE CAPITAL LP | 2,983,513 | $13,545,000 | 5.40% |
| Foresite Capital Management IV, LLC | 1,787,094 | $8,113,000 | 0.97% |
| Avoro Capital Advisors LLC | 10,300,000 | $46,762,000 | 0.81% |
| Boxer Capital, LLC | 4,000,000 | $18,160,000 | 0.62% |
| Sio Capital Management, LLC | 562,339 | $2,553,000 | 0.52% |
| ACUTA CAPITAL PARTNERS, LLC | 315,341 | $1,432,000 | 0.52% |
| CM Management, LLC | 150,000 | $681,000 | 0.51% |
| APIS CAPITAL ADVISORS, LLC | 120,000 | $545,000 | 0.50% |
| Versant Venture Management, LLC | 543,753 | $2,469,000 | 0.48% |